Vol 2, No 3 (2011)
Review paper
Published online: 2011-10-18
Bendamustine in therapy of lymphoid malignancies
Hematologia 2011;2(3):220-232.
Abstract
Bendamustine is cytotoxic agent combining structural and functional features of alkylating
agents and purine analogues. Many clinical trials confirmed efficacy of bendamustine in
therapy of lymphoid malignancies. This article summarizes results, clinical data and safety of
treatment with bendamustine in patients with non-Hodgkin lymphomas, chronic lymphocytic
leukemia and plasma cell myeloma.
Hematologia 2011; 2, 3: 220–232
Hematologia 2011; 2, 3: 220–232
Keywords: bendamustinenon-Hodgkin lymphomaschronic lymphocytic leukemiaplasma cell myeloma